Ï㽶ÊÓƵ

Brian J. Mickey
No Rating Available
(Learn About Our Rating System)

Brian J. Mickey, MD, PhD

Languages spoken: English

Clinical Locations

Huntsman Mental Health Institute

Salt Lake City
801-587-3297

  • Brian J. Mickey, MD, PhD, is Professor of Psychiatry. He studied physics and biology at the Ï㽶ÊÓƵ of Washington, Seattle, then completed his MD and PhD in Neuroscience at the Ï㽶ÊÓƵ of Michigan, Ann Arbor. After psychiatry residency and postdoctoral fellowship at the Molecular & Behavioral Neuroscience Institute, he joined the faculty at the Ï㽶ÊÓƵ of Michigan. In 2015, he moved to the Ï㽶ÊÓƵ of Utah, where he is a faculty member in Psychiatry, Neuroscience, Biomedical Engineering, and Anesthesiology.

    Dr. Mickey is board-certified in Psychiatry. His clinical focus is treatment-resistant mood disorders. He provides pharmacologic treatments and brain stimulation interventions in the Treatment Resistant Mood Disorders Clinic at the Huntsman Mental Health Institute.

    The overall objectives of Dr. Mickey's lab are to understand how limbic and prefrontal brain circuits give rise to psychiatric problems such as depression, anxiety, and addiction, and to develop new circuit-targeted interventions that return the brain to a healthy state.

    Lab web site:

    Specialties

    Board Certification

    American Board of Psychiatry & Neurology (Psychiatry)

  • Brian J. Mickey, MD, PhD, is Professor of Psychiatry. He studied physics and biology at the Ï㽶ÊÓƵ of Washington, Seattle, then completed his MD and PhD in Neuroscience at the Ï㽶ÊÓƵ of Michigan, Ann Arbor. After psychiatry residency and postdoctoral fellowship at the Molecular & Behavioral Neuroscience Institute, he joined the faculty at the Ï㽶ÊÓƵ of Michigan. In 2015, he moved to the Ï㽶ÊÓƵ of Utah, where he is a faculty member in Psychiatry, Neuroscience, Biomedical Engineering, and Anesthesiology.

    Dr. Mickey is board-certified in Psychiatry. His clinical focus is treatment-resistant mood disorders. He provides pharmacologic treatments and brain stimulation interventions in the Treatment Resistant Mood Disorders Clinic at the Huntsman Mental Health Institute.

    The overall objectives of Dr. Mickey's lab are to understand how limbic and prefrontal brain circuits give rise to psychiatric problems such as depression, anxiety, and addiction, and to develop new circuit-targeted interventions that return the brain to a healthy state.

    Lab web site:

    Board Certification and Academic Information

    Academic Departments Psychiatry -Primary
    Academic Divisions Adult Psychiatry
    Board Certification
    American Board of Psychiatry & Neurology (Psychiatry)

    Education history

    Research Fellow Ï㽶ÊÓƵ of Michigan, Molecular & Behavioral Neuroscience Institute Research Fellow
    Residency Psychiatry - Ï㽶ÊÓƵ of Michigan Health System Resident
    Professional Medical Medicine, Neuroscience - Ï㽶ÊÓƵ of Michigan Medical School M.D., Ph.D.
    Undergraduate Physics, Biology, dual major - Ï㽶ÊÓƵ of Washington B.S.

    Selected Publications

    Journal Article

    1. Rush, Conway, Aaronson, George, Riva-Posse, Dunner, Zajecka, Bunker, Quevedo, Allen, Alvan, Luing, Nahas, Manu, Bennett, Mickey BJ, Becker, Sheline, Cusin, Murrough, Reeves, Rosenquist, Leek, Majewski, Way, Olin, Sackheim (2024). Effects of Vagus Nerve Stimulation on Daily Function and Quality of Life in Markedly Treatment-Resistant Major Depression: Findings From a One-Year, Randomized, Sham-Controlled Trial. Brain Stimul, in press.
    2. Conway, Aaronson, Sackheim, George, Zajecka, Bunker, Duffy, Stedman, Riva-Posse, Allen, Quevedo, Berger, Alva, Malik, Dunner, Cichowicz, Banov, Manu, Nahas, Macaluso, Mickey BJ, Sheline, Kriedt, Lee, Gordon, Shy, Tran, Yates, Rush (2024). Vagus Nerve Stimulation in Treatment-Resistant Depression: A One-Year, Randomized, Sham-Controlled Trial. Brain Stimul, in press.
    3. Feldman DA, Jones KG, Vonesh LC, Jacobs R, Hoffman N, Lybbert C, Huang J, Kuck K, Odell D, Tadler SC, Mickey BJ (2024). Immediate Effects of Propofol on Mood: A Randomized Comparison of Two Doses in a Cohort with Depression. Psychopharmacology (Berl), in press.
    4. Riis TS, Feldman DA, Kwon SS, Vonesh LC, Koppelmans V, Brown JR, Solzbacher D, Kubanek J, Mickey BJ (2024). Noninvasive modulation of subcallosal cingulate and depression with focused ultrasonic waves. Biol Psychiatry, in press.
    5. Thurston MD, Ericksen LC, Jacobson MM, Koppelmans V, Mickey BJ, Love TM (2024). Oxytocin Differentially Modulates Reward System Responses to Social and Non-Social Incentives. Psychopharmacology (Berl), in press.
    6. Franklin, Achtyes, Altinay, Bailey, Bhati, Carr, Conroy, Husain, Khurshid, Lencz, McDonald, Mickey BJ, Murrough, Nestor, Nickl-Jockschat, Nikayin, Reeves, Reti, Selek, Sanacora, Trapp, Viswanath, Wright, Sullivan, Zandi, Potash (2024). The Genetics of Severe Depression. Mol Psychiatry, in press.
    7. Provenza NR, Reddy S, Allam A, Rajesh SV, Diab N, Reyes G, Caston RM, Katlowitz KA, Gandhi AD, Bechtold R, Dang HQ, Najera RA, Giridharan N, Kabotyanski K, Momin F, Hasen M, Banks GP, Mickey BJ, Kious BM, Shofty B, Hayden BY, Herron JA, Storch EA, Patel AB, Goodman WK, Sheth SA (2024). Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med, in press.
    8. Conway, Aaronson, Sackheim, Duffy, Stedman, Quevedo, Allen, Riva-Posse, Berger, Alva, Malik, Dunner, Cichowicz, Luing, Zajecka, Nahas, Mickey BJ, Kablinger, Kriedt, Bunker, Lee, Shy, Majewski, Olin, Tran, Rush (2024). Clinical Characteristics and Treatment Exposure of Patients with Marked Treatment-Resistant Unipolar Major Depressive Disorder: A RECOVER Trial Report. Brain Stimul, 17(2), 448-459.
    9. Riis T, Losser A, Feldman D, Mickey B, Kubanek J (2024). Device for multifocal delivery of ultrasound into deep brain regions in humans. IEEE Trans Biomed Eng, 71(2), 660-668.
    10. Riis TS, Feldman DA, Mickey BJ, Kubanek J (2024). Controlled noninvasive modulation of deep brain regions in humans. Commun Eng, 3, 13.
    11. Shah SB, Peddada TN, Song C, Mensah M, Sung H, Yavi M, Yuan P, Zarate CA, Mickey BJ, Burmeister M, Akula N, McMahon FJ (2023). Exome-wide Association Study of Treatment-Resistant Depression Suggests Novel Treatment Targets. Sci Rep, 13(1), 12467.
    12. Jones KG, Lybbert C, Euler MJ, Huang J, Lunt S, Richards SV, Jessop JE, Larson A, Odell DH, Kuck K, Tadler SC, Mickey BJ (2023). Diversity of electroencephalographic patterns during propofol-induced burst suppression. Frontiers in Systems Neuroscience, 17, 1172856.
    13. Baker AK, Ericksen LC, Koppelmans V, Mickey BJ, Martucci KT, Zubieta JK, Love TM (2022). Altered Reward Processing and Sex Differences in Chronic Pain. Front Neurosci, 16, 889849. ()
    14. Mickey BJ, Ginsburg Y, Jensen E, Maixner DF (2022). Distinct predictors of short- versus long-term depression outcomes following electroconvulsive therapy. J Psychiatr Res, 145, 159-166.
    15. Warthen KG, Welsh RC, Sanford B, Koppelmans V, Burmeister M, Mickey BJ (2021). Neuropeptide Y Variation Is Associated With Altered Static and Dynamic Functional Connectivity of the Salience Network. Front Syst Neurosci, 15, 629488. ()
    16. Langenecker SA, Westlund Schreiner M, Thomas LR, Bessette KL, DelDonno SR, Jenkins LM, Easter RE, Stange JP, Pocius SL, Dillahunt AK, Love TM, Phan KL, Koppelmans V, Paulus JP, Lindquist M, Caffo B, Mickey BJ, Welsh RC (2021). Using network parcels and resting state networks to estimate correlates of mood disorder and related research domain criteria constructs of reward responsiveness and inhibitory control. Biol Psychiatry Cogn Neurosci Neuroimaging, 7(1), 76-84.
    17. Lex H, Nevers SW, Jensen EL, Ginsburg Y, Maixner DF, Mickey BJ (2021). Long-term quality of life in treatment-resistant depression after electroconvulsive therapy. J Affect Disord, 291, 135-139.
    18. Pierson MD, Mickey BJ, Gilley LB, Weeks HR (2021). Outcomes of Youth Treated with Electroconvulsive Therapy. J Clin Psychiatry, 82(2), 17-22.
    19. Warthen KG, Boyse-Peacor A, Jones KG, Sanford B, Love TM, Mickey BJ (2020). Sex differences in the human reward system: Convergent behavioral, autonomic, and neural evidence. Soc Cogn Affect Neurosci, 15(7), 789-801.
    20. Soda T, McLoughlin DM, Clark SR, Oltedal L, Kessler U, Haavik J, Bousman C, Smith DJ, Bioque M, Clements CC, Loo C, Vila-Rodriguez F, Minelli A, Mickey BJ, Milev R, Docherty AR, Langan Martin J, Achtyes ED, Arolt V, Redlich R, Dannlowski U, Cardoner N, Clare E, Craddock N, Di Florio A, Dmitrzak-Weglarz M, Forty L, Gordon-Smith K, Husain M, Ingram WM, Jones L, Jones I, Juruena M, Kirov G, Landn M, Mller DJ, Nordenskld A, Plsson E, Paul M, Permoda A, Pliszka B, Rea J, Schubert KO, Sonnen JA, Soria V, Stageman W, Takamiya A, Urretavizacaya M, Watson S, Zavorotny M, Young AH, Vieta E, Rybakowski JK, Gennarelli M, Zandi PP, Sullivan PF, Baune BT (2019). International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). Eur Arch Psychiatry Clin Neurosci, 270(7), 921-932. ()
    21. DelDonno SR, Mickey BJ, Pruitt PJ, Stange JP, Hsu DT, Weldon AL, Zubieta JK, Langenecker SA (2019). Influence of childhood adversity, approach motivation traits, and depression on individual differences in brain activation during reward anticipation. Biol Psychol, 146, 107709. ()
    22. Langenecker SA, Mickey BJ, Eichhammer P, Sen S, Elverman KH, Kennedy SE, Heitzeg MM, Ribeiro SM, Love TM, Hsu DT, Koeppe RA, Watson SJ, Akil H, Goldman D, Burmeister M, Zubieta JK (2019). Cognitive Control as a 5-HT1A-Based Domain That Is Disrupted in Major Depressive Disorder. Front Psychol, 10, 691. ()
    23. Warthen KG, Sanford B, Walker K, Jones KG, Angstadt M, Sripada C, Goldman D, Zubieta JK, Welsh RC, Burmeister M, Mickey BJ (2019). Neuropeptide Y and representation of salience in human nucleus accumbens. Neuropsychopharmacology, 44(3), 495-502. ()
    24. Lex H, Ginsburg Y, Sitzmann AF, Grayhack C, Maixner DF, Mickey BJ (2019). Quality of life across domains among individuals with treatment-resistant depression. J Affect Disord, 243, 401-407. ()
    25. Kious BM, Bakian A, Zhao J, Mickey B, Guille C, Renshaw P, Sen S (2019). Altitude and risk of depression and anxiety: findings from the intern health study. Int Rev Psychiatry, 31(7-8), 637-645. ()
    26. Mickey BJ, White AT, Arp AM, Leonardi K, Torres MM, Larson AL, Odell DH, Whittingham SA, Beck MM, Jessop JE, Sakata DJ, Bushnell LA, Pierson MD, Solzbacher D, Kendrick EJ, Weeks HR 3rd, Light AR, Light KC, Tadler SC (2018). Propofol for Treatment-Resistant Depression: A Pilot Study. Int J Neuropsychopharmacol, 21(12), 1079-1089. ()
    27. Kang GE, Mickey BJ, McInnis MG, Krembs BS, Gross MM (2018). Motor behavior characteristics in various phases of bipolar disorder revealed through biomechanical analysis: Quantitative measures of activity and energy variables during gait and sit-to-walk. Psychiatry Res, 269, 93-101. ()
    28. Mickey BJ, Ginsburg Y, Sitzmann AF, Grayhack C, Sen S, Kirschbaum C, Maixner DF, Abelson JL (2018). Cortisol trajectory, melancholia, and response to electroconvulsive therapy. J Psychiatr Res, 103, 46-53. ()
    29. Tadler SC, Mickey BJ (2018). Emerging evidence for antidepressant actions of anesthetic agents. Curr Opin Anaesthesiol, 31(4), 439-445. ()
    30. Pecina M, Sikora M, Avery ET, Heffernan J, Pecina S, Mickey BJ, Zubieta JK (2017). Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. Eur Neuropsychopharmacol, 27(10), 977-986. ()
    31. Mickey BJ, Heffernan J, Heisel C, Pecia M, Hsu DT, Zubieta JK, Love TM (2016). Oxytocin modulates hemodynamic responses to monetary incentives in humans. Psychopharmacology (Berl), 233(23-24), 3905-3919. ()
    32. Gluskin BS, Mickey BJ (2016). Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Transl Psychiatry, 6, e747. ()
    33. Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta JK, Pecia M (2015). Salience Network Functional Connectivity Predicts Placebo Effects in Major Depression. Biol Psychiatry Cogn Neurosci Neuroimaging, 1(1), 68-76. ()
    34. DelDonno SR, Weldon AL, Crane NA, Passarotti AM, Pruitt PJ, Gabriel LB, Yau W, Meyers KK, Hsu DT, Taylor SF, Heitzeg MM, Herbener E, Shankman SA, Mickey BJ, Zubieta JK, Langenecker SA (2015). Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder. Psychiatry Res, 230(1), 56-64. ()
    35. Pecina M, Bohnert AS, Sikora M, Avery ET, Langenecker SA, Mickey BJ, Zubieta JK (2015). Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. JAMA Psychiatry, 72(11), 1087-94. ()
    36. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015). Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry, 76(10), 1374-84. ()
    37. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, Mickey BJ, Koeppe RA, Langenecker SA, Zubieta JK (2015). It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry, 20(2), 193-200. ()
    38. Lohoff FW, Hodge R, Narasimhan S, Nall A, Ferraro TN, Mickey BJ, Heitzeg MM, Langenecker SA, Zubieta JK, Bogdan R, Nikolova YS, Drabant E, Hariri AR, Bevilacqua L, Goldman D, Doyle GA (2014). Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry, 19(1), 129-39. ()
    39. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, Ni L, Walker SJ, Mickey BJ, Korycinski ST, Koeppe RA, Crocker JK, Langenecker SA, Zubieta JK (2013). Response of the mu-opioid system to social rejection and acceptance. Mol Psychiatry, 18(11), 1211-7. ()
    40. Pecia M, Mickey BJ, Love T, Wang H, Langenecker SA, Hodgkinson C, Shen PH, Villafuerte S, Hsu D, Weisenbach SL, Stohler CS, Goldman D, Zubieta JK (2013). DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex, 49(3), 877-90. ()
    41. Love TM, Enoch MA, Hodgkinson CA, Pecina M, Mickey B, Koeppe RA, Stohler CS, Goldman D, Zubieta JK (2012). Oxytocin gene polymorphisms influence human dopaminergic function in a sex-dependent manner. Biol Psychiatry, 72(3), 198-206. ()
    42. Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA, Stohler CS, Goldman D, Zubieta JK (2012). Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans. J Neurosci, 32(27), 9344-50. ()
    43. Hsu DT, Mickey BJ, Langenecker SA, Heitzeg MM, Love TM, Wang H, Kennedy SE, Pecia M, Shafir T, Hodgkinson CA, Enoch MA, Goldman D, Zubieta JK (2012). Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing. J Neurosci, 32(9), 3253-60. ()
    44. Mickey BJ, Zhou Z, Heitzeg MM, Heinz E, Hodgkinson CA, Hsu DT, Langenecker SA, Love TM, Pecia M, Shafir T, Stohler CS, Goldman D, Zubieta JK (2011). Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry, 68(2), 158-66. ()
    45. Mickey BJ, Ducci F, Hodgkinson CA, Langenecker SA, Goldman D, Zubieta JK (2008). Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J Neurosci, 28(44), 11354-9. ()

    Book Chapter

    1. Hristidis VC, Nagele P, Palanca BJ, Tadler SC, Mickey BJ, Gott BM, Conway CR (2024). The Use of Inhaled Gases in Psychiatry. In Quevedo, Brunoni, Hamani (Eds.), Interventional Psychiatry (pp. 383-401). Academic Press.
    2. Conway CR, Mickey BJ, Palanca BJ, Tadler SC, Nagele P (2022). Inhaled Gases for Treatment-Resistant Major Depression. In Quevedo, Riva-Posse, Bobo (Eds.), Managing Treatment-Resistant Depression (pp. 481-491). Academic Press.
    3. Sen S, Mickey BJ, Greden JF (2011). Psychopharmacological Roadmap for Treatment Resistant Depression. In Greden, et al (Eds.), Treatment Resistant Depression (pp. 33-49). American Psychiatric Publishing, Inc.

    Commentary

    1. Mickey BJ (2016). Genetic variation and the D2 dopamine receptor: implications for the treatment of neuropsychiatric disease. Pharmacogenomics, 17(11), 1207-1210. ()

  • News & Podcasts

    News

    Podcasts

  • Clinical Trials